FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080370935> ?p ?o ?g. }

• W3080370935 endingPage "e000870" @default.
• W3080370935 startingPage "e000870" @default.
• W3080370935 abstract "Background M4112 is an oral, potent, and selective indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase 2 (TDO2) dual inhibitor. Here, we report preclinical data and first-in-human phase I data, including safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy, of M4112 monotherapy in patients with advanced solid tumors. Methods In preclinical studies, M4112 was administered to mice with IDO1-expressing tumors to determine tumor IDO1 and liver TDO2 inhibition. In the phase I trial, patients received doses of M4112 two times per day in 28-day cycles until progression, toxicity, or withdrawal of consent. The primary objective was to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D). The primary endpoint was the incidence of dose-limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and treatment-emergent changes in safety parameters. Other endpoints included pharmacokinetics, pharmacodynamics, and antitumor effects. Results In mice, M4112 significantly decreased the kynurenine:tryptophan ratio in the liver and tumor. Fifteen patients received M4112 at five distinct dose levels (three patients per cohort: 100, 200, 400, 600, and 800 mg two times per day orally). Initially, all doses inhibited IDO1 ex vivo, but plasma kynurenine levels returned to or exceeded baseline levels after day 15. Despite initial changes in kynurenine, there was no significant reduction of plasma kynurenine at steady state. There was one DLT (grade 3 allergic dermatitis; 800 mg two times per day) and one grade 2 QT prolongation (800 mg two times per day), resulting in dose reduction (not a DLT). M4112 was well tolerated, and neither the MTD nor the RP2D was established. TEAEs included fatigue, nausea, and vomiting. The best overall response was stable disease (n=9, 60%). Conclusions There were no serious safety concerns at any dose. Although M4112 inhibited IDO1 activity ex vivo, plasma kynurenine levels were not reduced despite achieving target exposure. Trial registration number NCT03306420 ." @default.
• W3080370935 created "2020-09-01" @default.
• W3080370935 creator A5000707431 @default.
• W3080370935 creator A5005436649 @default.
• W3080370935 creator A5022467575 @default.
• W3080370935 creator A5037774305 @default.
• W3080370935 creator A5044331807 @default.
• W3080370935 creator A5045982804 @default.
• W3080370935 creator A5049548374 @default.
• W3080370935 creator A5061237827 @default.
• W3080370935 creator A5070258271 @default.
• W3080370935 creator A5082885356 @default.
• W3080370935 creator A5090786280 @default.
• W3080370935 date "2020-08-01" @default.
• W3080370935 modified "2023-10-07" @default.
• W3080370935 title "Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors" @default.
• W3080370935 cites W1834981029 @default.
• W3080370935 cites W1902958101 @default.
• W3080370935 cites W1966481035 @default.
• W3080370935 cites W1990395010 @default.
• W3080370935 cites W1992374256 @default.
• W3080370935 cites W1998142996 @default.
• W3080370935 cites W2007489575 @default.
• W3080370935 cites W2010378562 @default.
• W3080370935 cites W2012836981 @default.
• W3080370935 cites W2019607817 @default.
• W3080370935 cites W2030923896 @default.
• W3080370935 cites W2076232020 @default.
• W3080370935 cites W2087801719 @default.
• W3080370935 cites W2094530868 @default.
• W3080370935 cites W2094644987 @default.
• W3080370935 cites W2097995306 @default.
• W3080370935 cites W2113846910 @default.
• W3080370935 cites W2127903252 @default.
• W3080370935 cites W2134670672 @default.
• W3080370935 cites W2281741663 @default.
• W3080370935 cites W2306053308 @default.
• W3080370935 cites W2333895855 @default.
• W3080370935 cites W2335128695 @default.
• W3080370935 cites W2341418203 @default.
• W3080370935 cites W2570766240 @default.
• W3080370935 cites W2602843166 @default.
• W3080370935 cites W2809526912 @default.
• W3080370935 cites W2898007396 @default.
• W3080370935 cites W744787342 @default.
• W3080370935 doi "https://doi.org/10.1136/jitc-2020-000870" @default.
• W3080370935 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7449315" @default.
• W3080370935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32843490" @default.
• W3080370935 hasPublicationYear "2020" @default.
• W3080370935 type Work @default.
• W3080370935 sameAs 3080370935 @default.
• W3080370935 citedByCount "19" @default.
• W3080370935 countsByYear W30803709352021 @default.
• W3080370935 countsByYear W30803709352022 @default.
• W3080370935 countsByYear W30803709352023 @default.
• W3080370935 crossrefType "journal-article" @default.
• W3080370935 hasAuthorship W3080370935A5000707431 @default.
• W3080370935 hasAuthorship W3080370935A5005436649 @default.
• W3080370935 hasAuthorship W3080370935A5022467575 @default.
• W3080370935 hasAuthorship W3080370935A5037774305 @default.
• W3080370935 hasAuthorship W3080370935A5044331807 @default.
• W3080370935 hasAuthorship W3080370935A5045982804 @default.
• W3080370935 hasAuthorship W3080370935A5049548374 @default.
• W3080370935 hasAuthorship W3080370935A5061237827 @default.
• W3080370935 hasAuthorship W3080370935A5070258271 @default.
• W3080370935 hasAuthorship W3080370935A5082885356 @default.
• W3080370935 hasAuthorship W3080370935A5090786280 @default.
• W3080370935 hasBestOaLocation W30803709351 @default.
• W3080370935 hasConcept C111113717 @default.
• W3080370935 hasConcept C112705442 @default.
• W3080370935 hasConcept C126322002 @default.
• W3080370935 hasConcept C185592680 @default.
• W3080370935 hasConcept C197934379 @default.
• W3080370935 hasConcept C203092338 @default.
• W3080370935 hasConcept C2776706248 @default.
• W3080370935 hasConcept C2776710720 @default.
• W3080370935 hasConcept C2777503454 @default.
• W3080370935 hasConcept C2778375690 @default.
• W3080370935 hasConcept C515207424 @default.
• W3080370935 hasConcept C535046627 @default.
• W3080370935 hasConcept C55493867 @default.
• W3080370935 hasConcept C71924100 @default.
• W3080370935 hasConcept C83478079 @default.
• W3080370935 hasConcept C90924648 @default.
• W3080370935 hasConcept C98274493 @default.
• W3080370935 hasConceptScore W3080370935C111113717 @default.
• W3080370935 hasConceptScore W3080370935C112705442 @default.
• W3080370935 hasConceptScore W3080370935C126322002 @default.
• W3080370935 hasConceptScore W3080370935C185592680 @default.
• W3080370935 hasConceptScore W3080370935C197934379 @default.
• W3080370935 hasConceptScore W3080370935C203092338 @default.
• W3080370935 hasConceptScore W3080370935C2776706248 @default.
• W3080370935 hasConceptScore W3080370935C2776710720 @default.
• W3080370935 hasConceptScore W3080370935C2777503454 @default.
• W3080370935 hasConceptScore W3080370935C2778375690 @default.
• W3080370935 hasConceptScore W3080370935C515207424 @default.
• W3080370935 hasConceptScore W3080370935C535046627 @default.
• W3080370935 hasConceptScore W3080370935C55493867 @default.

• next